This is an amendment to 16.19.20 NMAC, Section 65, 66, 67, and 68 effective 11/17/2026.

16.19.20.65 SCHEDULE I:

A. Section 30-31-6 NMSA 1978, schedule I shall consist of the following drugs and other substances, by whatever name, common or usual name, chemical name or brand name designated, listed in this section; **Opioids**, unless specifically exempt or unless listed in another schedule, any of the following opioids, including its isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation.

(1) Acetylmethadol;
(2) Allylprodine;
(3) Alphacetylmethadol;
(4) Alphameprodine;
(5) Alphamethadol;
(6) Alpha-methyl fentanyl;
(7) Benzethidine;
(8) Betacetylmethadol;
(9) Betameprodine;
(10) Betamethadol;
(11) Betaprodine;
[~~**(12)** Clonitazene;~~]
[~~**(13)**~~] **(12)** Desmethyltramadol;
[~~**(14)**~~] **(13)** Dextromoramide;
[~~**(15)**~~] **(14)** Diampromide;
[~~**(16)**~~] **(15)** Diethylthiambutene;
[~~[**(17)**] Dimethylthiambutene;~~]
[~~**(18)**~~] **(16)** Difenoxin;
[~~**(19)**~~] **(17)** Dimenoxadol;
[~~**(20)**~~] **(18)** Dimepheptanol;
[~~**(21)**~~] **(19)** Dimethylthiambutene;
[~~**(22)**~~] **(20)** Dioxaphetyl Butyrate;
[~~**(23)**~~] **(21)** Dipipanone;
[~~**(24)**~~] **(22)** Ethylmethylthiambutene;
[~~**(25)** Etonitazene;~~]
[~~**(26)**~~] **(23)** Etoxeridine;
[~~**(27)**~~] **(24)** Furethidine;
[~~**(28)**~~] **(25)** Hydroxypethidine;
[~~**(29)** Isotonitazene;~~]
[~~**(30)**~~] **(26)** Ketobemidone;
[~~**(31)**~~] **(27)** Levomoramide;
[~~**(32)**~~] **(28)** Levophenacylmorphan;
[~~**(33)**~~] **(29)** Morpheridine;
[~~**(34)**~~] **(30)** Noracymethadol;
[~~**(35)**~~] **(31)** Norlevorphanol;
[~~**(36)**~~] **(32)** Normethadone;
[~~**(37)**~~] **(33)** Norpipanone;
[~~**(38)**~~] **(34)** Phenadoxone;
[~~**(39)**~~] **(35)** Phenampromide;
[~~**(40)**~~] **(36)** Phenomorphan;
[~~**(41)**~~] **(37)** Phenoperidine;
[~~**(42)**~~] **(38)** Piritramide;
[~~**(43)**~~] **(39)** Proheptazine;
[~~**(44)**~~] **(40)** Properidine;
[~~**(45)**~~] **(41)** Propiram;

[~~(46)~~] **(42)** Racemoramide;
[~~(47)~~] **(43)** Tilidine;
[~~(48)~~] **(44)** Trimeperidine
[~~(49)~~] **(45)** U-48800; (2-(2,4-dichlorophenyl)-N-((1S,2S)-2-(dimethylamino)cyclohexyl)-N-methylacetamide, monohydrochloride;
[~~(50)~~] **(46)** U-49900; (trans-3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methyl-benzamide;
[~~(51)~~] **(47)** Beta-Hydroxy-3-Methylfentanyl;
[~~(52)~~] **(48)** 3-Methylthiofentanyl;
[~~(53)~~] **(49)** Acetyl-Alpha-Methyl fentanyl ;
[~~(54)~~] **(50)** Alpha-Methylthiofentanyl ;
[~~(55)~~] **(51)** Beta-hydroxyfentanyl ;
[~~(56)~~] **(52)** Para-Fluoro[-]fentanyl;
[~~(57)~~] **(53)** Thiofentanyl;
[~~(58)~~] **(54)** Acetyl fentanyl;
[~~(59)~~] **(55)** Butyryl fentanyl;
[~~(60)~~] **(56)** Betahydroxythiofentanyl;
[~~(61)~~] **(57)** Furanyl fentanyl;
[~~(62)~~] **(58)** AH-7921; (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide);
[~~(63)~~] **(59)** U47700; (trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide);
[~~(64)~~] **(60)** MT-45; (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine)[~~(4-Nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide)~~];
[~~(65)~~] **(61)** W-15; (4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]-benzenesulfonamide);
[~~(66)~~] **(62)** W-18; (1-(4-Nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide);
[~~(67)~~] **(63)** U-50488; (2-(3,4-dichlorophenyl)-N-methyl-N-[(1R,2R)-2-pyrrolidin-1-ylcyclohexyl]acetamide);
[~~(68)~~] **(64)** U50488H; ((-)(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)cyclo-hexyl]benzeneacetamide).
[~~(69)~~] **(65)** Fentanyl-related substances, their isomers, esters, ethers, salts, and salts of isomers, esters and ethers. Fentanyl-related substance means any substance, unless specifically exempted or unless listed in another schedule, that is structurally related to fentanyl by one or more of the following modifications:
(a) replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;
(b) substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro groups;
(c) substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups;
(d) replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; or
(e) replacement of the N-propionyl group by another acyl group; or
(f) any combination of the above substances include, but are not limited to, the following substances: (reserved)
[~~(70)~~] **(66)** Acryl Fentanyl;
[~~(71) 4F-butyrfentanyl;~~]
[~~(72) 4-methoxybutyrfentanyl;~~]
[~~(73) Fluorobutyrfentanyl;~~]
[~~(74)~~] **(67)** Fluorofentanyl;
[~~(75)~~] **(68)** FIBF; (Para Fluoro[-]Isobutyryl Fentanyl);
[~~(76)~~] **(69)** Cyclopropyl fentanyl;
[~~(77)~~] **(70)** Thiofuranyl fentanyl (Thiophene fentanyl);
[~~(78)~~] **(71)** 3-methylfentanyl (N-3-methyl-1-(2-phenyl-ethyl)-4-Piperidinyl)-N-phenylpropanamide, its optical and geometric isomers, salts and salts of isomers;
[~~(79)~~] **(72)** crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2- enamide);
[~~(80)~~] **(73)** valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide);

[~~(81)~~] **(74)** N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide (2′-fluoro ortho-fluorofentanyl; 2′-fluoro 2-fluorofentanyl);

[~~(82)~~] **(75)** N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide (4′-methyl acetyl fentanyl);

[~~(83)~~] **(76)** beta-phenyl fentanyl or N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide (β′-phenyl fentanyl; beta′-Phenyl fentanyl; 3-phenylpropanoyl fentanyl);

[~~(84)~~] **(77)** beta-methyl fentanyl or N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide (β-methyl fentanyl);

(78) beta-Methylacetyl fentanyl (N-phenyl-N-(1-(2- phenylpropyl)piperidin-4-yl)acetamid

[~~(85)~~] **(79)** N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (ortho-fluorobutyryl fentanyl; 2-fluorobutyryl fentanyl);

[~~(86)~~] **(80)** (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl acetylfentanyl; 2-methyl acetylfentanyl);

[~~(87)~~] **(81)** 2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl methoxyacetylfentanyl; 2-methyl methoxyacetyl fentanyl);

[~~(88)~~] **(82)** N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (para-methylfentanyl; 4-methylfentanyl);

[~~(89)~~] **(83)** N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide (phenyl fentanyl; benzoyl fentanyl);

[~~(90)~~] **(84)** N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide (thiofuranyl fentanyl; 2-thiofuranyl fentanyl; thiophene fentanyl);

[~~(91)~~] **(85)** Ethyl (1-phenethylpiperidin-4- yl)(phenyl)carbamate (fentanyl carbamate);

[~~(92)~~] **(86)** N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)acrylamide (ortho-fluoroacryl fentanyl);

[~~(93)~~] **(87)** N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)isobutyramide (ortho-fluoroisobutyryl fentanyl);

[~~(94)~~] **(88)** N-(4-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)furan-2- carboxamide (para-fluoro furanyl fentanyl);

[~~(95)~~] **(89)** Cyclopentyl fentanyl;

[~~(96)~~] **(90)** Isobutyryl fentanyl;

[~~(97)~~] **(91)** Para-chloroisobutyryl fentanyl;

[~~(98)~~] **(92)** Para-methoxybutyryl fentanyl or 4-MeO-BF; N-(4-Methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide;

[~~(99)~~] **(93)** Para-fluorobutyryl fentanyl or 4-FBF; N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide;

[~~(100)~~] **(94)** Ocfentanil;

[~~(101)~~] **(95)** Ortho-Fluorofentanyl;

[~~(102)~~] **(96)** Tetrahydrofuranyl Fentanyl;

[~~(103)~~] **(97)** Methoxyacetyl Fentanyl; 2-Methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide;

[~~(104)~~] **(98)** 4-Fluoroisobutyryl Fentanyl;

[~~**(105)** Para-Fluorofentany;l~~

~~**(106)** Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1Hbenzimidazol-1-yl)-N,N-diethylethan-1-amine);~~

~~**(107)** Etodesnitazene; etazene (2-(2-(4-ethoxybenzyl)-1Hbenzimidazol-1-yl)-N,N-diethylethan-1-amine);~~

~~**(108)** Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);~~

~~**(109)** Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine);~~

~~**(110)** Metodesnitazene (N,6N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine);~~

~~**(111)** Protonitazene (N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine);~~

~~**(112)**~~] **(99)** Brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2 H-benzo[*d*]imidazol-2-one);

[~~(113)~~] **(100)** Zipeprol (1-methoxy-3-[4-(2-methoxy-2- phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol).

(101) 2',5'-Dimethoxyfentanyl (N-(1-(2,5- dimethoxyphenethyl)piperidin-4-yl)-Nphenylpropionamide);

(102) 3-Furanyl Fentanyl; (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3-carboxamide);

(103) Alpha-Methyl Butyryl Fentanyl;

(104) Isovaleryl Fentanyl; (3-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide);

(105) Meta-Fluorofentanyl;

(106) Meta-Fluorofuranyl Fentanyl;

(107) Meta-Fluroisobutyryl Fentanyl;

(108) Ortho-Fluoro Furanyl Fentanyl; (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);

(109) Para-Methoxyfuranyl Fentanyl;

(110) Para-Methylcyclopropyl Fentanyl;

(111) 2-Methyl AP-237: (1-(2-methyl-4-(3-phenylprop-2-en-1- yl)piperazin-1-yl)butan-1-one);

(112) Dihydromorphine; Paramorphan;

(113) Ortho-Chlorofentanyl; (N-(2-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);

(114) Ortho-Methylcyclopropylfentanyl; (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);

(115) Para-Chlorofentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);

(116) Para-Fluoro valeryl fentanyl; (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)pentanamide);

(117) Tetrahydrothiophene fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrothiophene-2-carboxamide);

(118) Benzimidazole opioids; Nitazenes;

(a) 5-Methyl etodesnitazene[PD42.1]; 2-(2-(4-Ethoxybenzyl)-5-methyl-1H-benzimidazol-1-yl)- N,N-diethylethan-1-amine;

(b) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1Hbenzimidazol-1-yl)-N,N-diethylethan-1- amine);

(c) Clonitazene;

(d) Ethyleneoxynitazene; 2-(2-((2,3-Dihydrobenzofuran-5-yl)methyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine;

(e) Etodesnitazene; etazene (2-(2-(4-ethoxybenzyl)-1Hbenzimidazol-1-yl)-N,N-diethylethan-1- amine);

(f) Etonitazene;

(g) Flunitazene (N, N -diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1 H -benzimidazol-1-yl)ethan-1-amine);

(h) Isotonitazene;

(i) Methylenedioxynitazene; 3′,4′¬Methylenedioxynitazene; 2-(2-(Benzodioxol-5-ylmethyl)-5-nitro-1H-benzimidazol- 1-yl)-N,N-diethylethan-1-amine;

(j) Metodesnitazene (N,6 N -diethyl-2-(2-(4-methoxybenzyl)-1 H -benzimidazol-1-yl)ethan-1-amine);

(k) Metonitazene (N, N -diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1 H -benzimidazol-1-yl)ethan-1-amine);

(l) Metonitazepyne; 2-(4-Methoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole (N-pyrrolidino metonitazene);

(m) N-Desethyl etonitazene; 2-(2-(4-Ethoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-Nethylethan-1-amine;

(n) N-Desethyl isotonitazene (N-ethyl-2-(2-(4-isopropoxylbenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amin);

(o) N-Desethyl protonitazene: N-Ethyl-2-(5-nitro-2-(4-propoxybenzyl)-1Hbenzimidazol-1-yl)ethan-1-amine;

(p) N,N-Dimethylamino etonitazene; 2-(2-(4-Ethoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)- N,N-dimethylethan-1-amine;

(q) N-Pyrrolidino Etonitazene; Etonitazepyne;

(r) N-Piperidinyl Etonitazene; Etonitazepipne;

(s) N-Pyrrolidino isotonitazene; Isotonitazepyne; 2-(4-Isopropoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1- yl)ethyl)-1H-benzimidazole;

(t) Protonitazene (N, N -diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1 H -benzimidazol-1-yl)ethan-1-amine);

(u) Protonitazepyne; 5-Nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole (N-pyrrolidino protonitazene);

B. Opium derivatives: Unless specifically exempt or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation.

(1) Acetorphine;
(2) Acetyl dihydrocodeine; Acetylcodone;
(3) Benzyl morphine;
(4) Codeine methylbromide;
(5) Codeine-N-Oxide;
(6) Cyprenorphine;
(7) Desomorphine;
(8) Dehydro morphine; Pseudomorphine;
(9) Etorphine;
(10) Heroin; Diacetylmorphine, diamorphine;
(11) Hydromorphinol;
(12) Methyldesorphine;
(13) Methyldihydromorphine;
(14) Morphine methylbromide;
(15) Morphine methylsulfonate;
(16) Morphine-N-Oxide;
(17) Myrophine;
(18) Nicocodeine;
(19) Nicomorphine;
(20) Normorphine;
(21) Pholcodine;
(22) Thebacon;
(23) Drotebanol;
(24) 6AM; (6-acetylmorphine).

C. Stimulants: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers.

(1) Fenethylline;
(2) NEA; N-ethylamphetamine;
(3) cis-4-methylaminorex; U4Euh;
(4) N, N-dimethylamphetamine;
(5) (BZP), 1-benzylpiperazine; N-benzylpiperazine;
(6) (DCPP); 2,3-dichlorophenylpiperazine;
(7) (DBZP); dibenzylpiperazine;
(8) (MBZP); methylbenzylpiperazine;
(9) (mCPP); meta-chlorophenylpiperazine;
(10) (MDBZP); methylenedioxybenzylpiperazine;
(11) (meOPP); para-methoxyphenylpiperazine;
(12) (pCPP); para-chlorophenylpiperazine;
(13) (pFPP); para-fluorophenylpiperazine;
(14) (2-DPMP), desoxypipradrol; 2-diphenylmethylpiperidine;
(15) D2PM, diphenylprolinol; diphenyl-2-pyrrolidinemethanol;
(16) HDMP-28; methylnaphthidate;
(17) Nocaine, (+)-CPCA; 3α-carbomethoxy-4β-(4-chlorophenyl)-N-methylpiperidine;
(18) BTQ or butyltolylquinuclidine; (2-Butyl-3-(p-tolyl)quinuclidine;
(19) Methiopropamine; (N-methyl-1- (thiophen-2-yl)propan-2-amine);
(20) Mesocarb; (N-phenyl-N′ -(3-(1-phenylpropan-2-yl)-1,2,3- oxadiazol-3-ium-5-

yl)carbamimidate);

(21) Amineptine (7- [(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5- yl)amino]heptanoic acid);

(22) 4,4′-Dimethylaminorex (4,4′-DMAR; 4,5-dihydro-4- methyl-5-(4-methylphenyl)-2-oxazolamine; 4-methyl-5- (4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine).

(23) 4-CMC; 4-Chloromethcathinone;

(24) Ethylphenidate; (ethyl 2-phenyl-2-(piperidin-2-yl)acetate);

(25) 4-Fluoroamphetamine; 1-(4-fluorophenyl)propan-2-amine; para -fluoroamphetamine;

D. Depressants: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

(1) Mecloqualone;

(2) Methaqualone; Quaalude;

(3) Benzodiazepines;

(a) Bromazepam;

(b) Camazepam;

(c) Cloxazolam;

(d) Delorazepam;

(e) Ethylloflazepate;

(f) Fludiazepam;

(g) Flunitrazepam; Rohypnol;

(h) Haloxazolam;

(i) Ketazolam;

(j) Loprazolam;

(k) Lormetazepam;

(l) Medazepam;

(m) Nimetazepam;

(n) Nitrazepam;

(o) Nordiazepam;

(p) Oxazolam;

(q) Phenazepam

(r) Pinazepam;

(s) Tetrazepam;

(t) Flubromazepam;

(u) Diclazepam;

(v) Etizolam;

(w) Flualprazolam;

(x) Clonazolam;

(y) Flubromazolam;

(z) Bromazolam

(4) Gamma hydroxybutyric acid and any chemical compound that is metabolically converted to GHB;

(5) Gamma butyrolactone and any chemical compound that is metabolically converted to GHB;

(6) 1-4 butane diol and any chemical compound that is metabolically converted to GHB

(7) GHV or 4-methyl-GHB; γ-hydroxyvaleric acid;

(8) GVL; γ-valerolactone;

(9) MMQ; methylmethaqualone;

(10) MBQ; mebroqualone.

(11) 2-FDCK; 2-Fluorodeschloroketamine;

E. Hallucinogenic substances: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation (for purpose of this sub-section only, the term “isomers” includes the optical, positional, and geometric isomers).

(1) MDA; 3,4[-]-methylenedioxy[-]amphetamine;
(2) MMDA; 5[-]-[-]methoxy[-]- 3,4-methylenedioxy[-]amphetamine;
(3) TMA; 3,4,5[-]-trimethoxy[-]amphetamine;
(4) Bufotenine;
(5) DET; (Diethyltryptamine);
(6) DMT; (Dimethyltryptamine);
(7) DOM or STP; (4-methyl-2,5-dimethoxy amphetamine);
[~~**(8)** Lysergic acid amide;~~]
[~~**(9)**~~] **(8)** Lysergic acid diethylamide;
[~~**(10)**~~] **(9)** Mescaline;
[~~**(11)**~~] **(10)** Peyote;
[~~**(12)**~~] **(11)** N-ethyl-3-piperidyl benzilate; JB 318;
[~~**(13)**~~] **(12)** N-methyl-3-piperidyl benzilate; JB-336;
[~~**(14)**~~] **(13)** Psilocybin;
[~~**(15)**~~] **(14)** Psilocyn;
[~~**(16)**~~] **(15)** Parahexyl (synthetic analog of delta-9-tetrahydrocannabinol);
[~~**(17)**~~] **(16)** 2, 5 -dimethoxyamphetamine; 2, 5-DMA;
[~~**(18)**~~] **(17)** 4-bromo-2, 5-dimethoxy-amphetamine; 2, 5-DMA;
[~~**(19)**~~] **(18)** PMA; 4-methoxyamphetamine;
[~~**(20)**~~] **(19)** PCE; (Eticyclidine[~~ Ethylamine~~] N-ethyl-1-phenylcyclohexylamine);
[~~**(21)**~~] **(20)** Pyrrolidine 1-(1-phenylcyclohexyl)-pyrrolidine (PCPy), (PHP) analog of the drug phencyclidine;
[~~**(22)**~~] **(21)** Thiophene [~~(~~]analogs of phencyclidine[~~)~~] (TCP,[~~ or~~] T[~~P~~]CPy or BTCP);
[~~**(23)**~~] **(22)** Alpha-ethyltryptamine;
[~~**(24)**~~] **(23)** 2,[-]5-dimethoxy-4-ethylamphet[-]amine; DOET;
[~~**(25)**~~] **(24)** Ibogaine;
[~~**(26)**~~] **(25)** 2C-T-7; (2,5-dimethoxy-4-(n)-propylthiophenethylamine);
[~~**(27)**~~] **(26)** AMT; (Alpha-methyltryptamine);
[~~**(28)**~~] **(27)** 5-MeO-DIPT; (5-methoxy-N,N-diisopropyltryptamine);
[~~**(29)**~~] **(28)** 25B-NBOMe; (2-(4-bromo-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);
[~~**(30)**~~] **(29)** 25C-NBOMe; (2-(4-chloro-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);
[~~**(31)**~~] **(30)** 25I-NBOMe; (2-(4-iodo-2.5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine).
[~~**(32)**~~] **(31)** Synthetic cannabinoids: Unless specifically exempted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following synthetic cannabinoids which demonstrates binding activity to the cannabinoid receptor or analogs or homologs with binding activity. Substances include but are not limited to:
(a) CP 55,244 ((hydroxymethyl)-4-[2-hydroxy-4-(2-methyloctan-2-yl)phenyl] 1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ol);
(b) CP 55,940 (5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol);
(c) JWH-081 (1-pentyl-3-[1-(4-methoxynaphthoy)]indole);
(d) JWH-122 (1-pentyl-3-(4-methyl-1-naphthoyl)indole);
(e) JWH-133 3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro -6,6,9-trimethyl-6H dibenzo[b,d]pyran;
(f) JWH 203 1-pentyl-3-(2-chlorophenylacetyl)indole);
(g) JWH 210 4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone;
(h) AM-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole);
(i) AM-1221 (1-(N-methylpiperdin-2-yl)methyl-2-methyl-3-(1-naphthoyl)-6-nitroindole;
(j) AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole);
(k) RCS-4 or SR-19 (1-pentyl-3-[(4-methoxy)-benzoyl]indole);
(l) RCS-8 or SR-18 (1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole);
(m) JWH-018[~~210~~] (1-pentyl-3-(4-ethylnaphthoyl)indole);

(n) WIN-49,098 (Pravadoline) (4-methoxyphenyl)-[2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]methanone;

(o) WIN-55,212-2 (2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo-1,4-benzooxazin6- yl)-1-naphthalenylmethanone);

(p) any of the following synthetic cannabinoids, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation;

(i) naphthoylindoles: any compound containing a 3-(1- naphthoyl) indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, JWH-398 and AM-2201;

(ii) naphthylmethylindoles: any compound containing a1Hindol- 3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-175, JWH-184, and JWH-199;

(iii) naphthoylpyrroles: any compound containing a 3-(1- naphthoyl) pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-307;

(iv) naphthylmethylindenes: any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent including, but not limited to, JWH-176;

(v) phenylacetylindoles: any compound containing a 3- phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, JWH-203, JWH-250, JWH-251, and RCS-8;

(vi) cyclohexylphenols: any compound containing a 2-(3-hydroxycyclohexyl) phenol structure with substitution at the 5- position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group, whether or not substituted in the cyclohexyl ring to any extent including, but not limited to, Cannabicyclohexanol (CP 47,497 C8 homologue), CP 47,497 and CP 55,490;

(vii) benzoylindoles: any compound containing a 3-(benzoyl) [5] OTS-3833.4 indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4- morpholinyl) ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent including, but not limited to, AM-694, Pravadoline (WIN 48,098), RCS-4, and AM-1241;

(q) UR-144 1-(pentyl-1H-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl)methanone;

(r) XLR11 1-(5-fluoro-pentyl)-1H-indol-3-yl(2,2,3,3-tetramethylcyclopropyl)methanone;

(s) APINACA or AKB48 N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide;

(t) QUPIC or PB-22; Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate;

(u) 5-fluoro-PB22; 5F-PB22; Quinolin-8-yl 1-(5-fluropentyl-1H-indole-3-carboxylate;

(v) AB-FUBINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-flurobenzyl)-1H-indazole-3-carboxamide;

(w) ADB-PINACA; N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide;

(x) AB-CHMINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide;

(y) AB-PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide;

(z) THJ-2201; [1-(5-fluropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone;

(aa) FDU-PB-22[~~IUPAC~~]: 1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3 carboxylate;

(bb) 5-fluoro ABICA: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide;

(cc) FUB-144 or FUB-UR-144; [1-(4-fluorobenzyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;

(dd) MN-18; N-(1-Naphthyl)-1-pentyl-1H-indazole-3-carboxamide;

(ee) FUB-PB-22 or QUFUBIC; Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate;

~~[**(ff)** ADB-CHMINACA (N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);]~~

[~~**(gg)**~~] **(ff)** AMB-FUBINACA or FUB-AMB or MMB-FUBINACA **(**methyl(1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate);

[~~**(hh)**~~] **(gg)** 5-fluoro-AMB or 5F-AMB; (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate) [~~(N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine, methyl ester)~~];

~~[**(ii)** 5-fluoro-ADB (N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-methyl-D-valine, methyl ester);]~~

[~~**(jj)**~~] **(hh)** Bk-DMBDB or dibutylone; 1-(Benzo[d][1,3]dioxol-5-yl)-2-(dimethylamino)butan-1-one;

~~[**(kk)** MMB-FUBINACA; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate;]~~

[~~**(ll)**~~] **(ii)** MDMB-CHMICA or MMB-CHMINACA; methyl (S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate;

[~~**(mm)**~~] **(jj)** NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate;

[~~**(nn)**~~] **(kk)** 5-Fluoro-AKB48 or 5F-APINACA; N-((3s,5s,7s)-adamanta-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide;

[~~**(oo)**~~] **(ll)** 5-Fluoro-ADB or 5F-ADB or 5F-MDMB-PINACA; Methyl(S)-2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate;

~~[**(pp)** 5-Fluoro-AMB; N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine,methyl ester;]~~

[~~**(qq)**~~] **(mm)** MAB-CHMINACA or ADB-CHMINACA; N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cycohexylmethyl)-1H-indazole-3-carboxamide;

[~~**(rr)**~~] **(nn)** SDB-006; N-benzyl-1-pentyl-1H-indole-3-carboxamide;

[~~**(ss)**~~] **(oo)** Cumyl-PINACA or SGT-24; 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide;

[~~**(tt)**~~] **(pp)** Cumyl-PICA or SGT-56; 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide**;**

[~~**(uu)**~~] **(qq)** 5F-CUMYL-PINACA; SGT-25; 1-(5-Fluoropentyl)-N-(2-phenylpropan-2- yl)-1H-indazole-3-carboxamide;

[~~**(vv)**~~] **(rr)** 5F-EDMB-PINACA; Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)- 3,3-dimethylbutanoate;

~~[**(ww)** methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate [5F-ADB; 5F-MDMB-PINACA];]~~

[~~**(xx)**~~] **(ss)** *N* -(Adamantan-1-yl)-1-(4-fluorobenzyl)-1 *H* -indazole-3-carboxamide (FUB-AKB48; FUB-APINACA; AKB48 *N* -(4-fluorobenzyl));

[~~**(yy)**~~] **(tt)** 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-indazole-3-carboxamide (4-CN-CUMYL-BUTINACA, 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYL BINACA, CUMYL-4CN-BINACA, or SGT-78);

[~~**(zz)**~~] **(uu)** methyl 2-(1-(cyclohexylmethyl)-1 H-indole-3-carboxamido)-3-methylbutanoate (MMB-CHMICA or AMB-CHMICA);

[~~**(aaa)**~~] **(vv)** 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1 H-pyrrolo[2,3-b]pyridine-3-carboxamide (5F-CUMYL-P7AICA)

(ww) 4F-MDMB-BUTICA; (methyl 2-[[1-(4-fluorobutyl) indole-3-carbonyl] amino]-

3,3-dimethyl-butanoate);

(xx) 5F-EDMB-PICA; (ethyl 2-[[1-5-fluoropentyl) indole-3- carbonyl] amino-3,3-dimethyl-butanoate;

(yy) 5F-MDMB-PICA; Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate;

(zz) ADB-4EN-PINACA; (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-en-1-yl)-1H-indazole-3-carboxamide;

(aaa) CUMYL-PEGACLONE; SGT-151 (5-pentyl-2-(2-phenylpropan-2- yl) pyrido[4,3-B] indole-1-one;

(bbb) MDMB-4EN-PINACA; (methyl 3,3-dimethyl-2-(1-(pent-4- en-1-yl)-1H-indazole-3-carboxamido) butanoate);

(ccc) MMB-FUBICA; (methyl 2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamido)-3-methyl butanoate;

(ddd) ADB-BUTINACA; (N-(1-amino-3,3-dimethyl-1-oxobutan-2- yl)-1-butyl-1H-indazole-3-carboxamide);

(eee) 4F-MDMB-BINACA; 4F-MDMB-BUTINACA or methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3−dimethylbutanoate);

(fff) 5F-AB-PINACA; (N-(1-amino-3-methyl-1-oxobutan-2- yl)-1-(5-fluoropentyl)-1 H-indazole-3-carboxamide);

(ggg) ADB-FUBINACA; (N-(1-amino-3,3-dimethyl-1- oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3- carboxamide);

(hhh) MDMB–FUBINACA; (methyl 2-(1-(4-fluorobenzyl)-1Hindazole-3-carboxamido)-3,3-dimethylbutanoate);

[~~(33)~~] **(32)** Substances determined by the board to have the pharmacological effect of the substance, the risk to the public health by abuse of the substance and the potential of the substance to produce psychic or physiological dependence liability is similar to the substances described in Paragraph (1) or (2) of 30-31-23C NMSA 1978. Substances include but are not limited to:

(a) Salvia divinorum;

(b) Salvinorin A (methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-2*H*-benzo[f]isochromene-7-carboxylate);

[~~(34)~~] **(33)** (4-MEC); 4-methyl-ethylcathinone;

[~~(35)~~] **(34)** (4-EMC); 4-ethyl-methcathinone;

[~~(36)~~] **(35)** Ethcathinone; 2-ethylamino-1-phenyl-propan-1-one;

[~~(37)~~] **(36)** Ethylone; 3',4'-methylenedioxy-N-ethylcathinone;

[~~(38)~~] **(37)** Bk-MBDB, butylone; beta-keto-N-methyl-3,4-benzodioxyolybutanamine;

[~~(39)~~] **(38)** (NRG-1), naphyrone; naphthylpyrovalerone;

[~~(40)~~] **(39)** Metamfepramone; N,N-dimethylcathinone;

[~~(41)~~] **(40)** Alpha-PPP; alpha-pyrrolidinopropiophenone;

[~~(42)~~] **(41)** (α-PBP); alpha-pyrrolidinobutiophenone;

[~~(43)~~] **(42)** (MOPPP); 4'-methoxy-alpha-pyrrolidinopropiophenone;

[~~(44)~~] **(43)** (MαPPP); 4'-methyl-α-pyrrolidinopropiophenone;

[~~(45)~~] **(44)** (MDPPP); 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone;

[~~(46)~~] **(45)** (MDPBP); 3',4'-methylenedioxy-alpha-pyrrolidinobutiophenone;

[~~(47)~~] **(46)** (MPBP); 4'-methyl-α-pyrrolidinobutiophenone;

[~~(48)~~] **(47)** Alpha-PVP; alpha-pyrrolidinovalerophenone;

[~~(49)~~] **(48)** (MDAI); 5,6-methylenedioxy-2-aminoindane;

[~~(50)~~] **(49)** Buphedrone; alpha-methylamino-butyrophenone;

[~~(51)~~] **(50)** Eutylone; beta-keto-ethylbenzodioxolylbutanamine;

[~~(52)~~] **(51)** beta-keto-ethylbenzodioxolylpentanamine; (N-Ethylpentylone or Ephylone);

[~~(53)~~] **(52)** beta-keto-methylbenzodioxolylpentanamine (pentylone);

[~~(54)~~] **(53)** 4-Bromo-2,5-dimethoxyphenethylamine (2c-B, Nexus);

[~~(55)~~] **(54)** N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alphamethyl-3,4(methylenedioxy)-phenethylamine, and N-hydroxy MDA;

[~~(56)~~] **(55)** 5-methoxy-N,N-dimethyltryptamine (5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT;

[~~(57)~~] **(56)** Mephedrone or 4-MMC; 4-methylmethcathinone;

[~~(58)~~] **(57)** (MDPV); 3,4-methylenedioxypyrovalerone;
[~~(59)~~] **(58)** (2C-E) or aquarust; 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine;
[~~(60)~~] **(59)** (2C-D); 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine;
[~~(61)~~] **(60)** (2C-T-2); 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine;
[~~(62)~~] **(61)** (2C-T4); 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine;
[~~(63)~~] **(62)** (2C-H); 2-(2,5-Dimethoxyphenyl)ethanamine;
[~~(64)~~] **(63)** (2C-N); 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine;
[~~(65)~~] **(64)** (2C-P); 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine;
[~~(66)~~] **(65)** Methylone; 3,4-Methylenedioxy-N-methylcathinone;
[~~(67)~~] **(66)** Aminorex (2-amino-5-phenyl-2-oxazoline);
[~~(68)~~] **(67)** Pentedrone;
[~~(69)~~] **(68)** 4-FMC or flephedrone; 4-fluro-N-methylcathinone;
[~~(70)~~] **(69)** (3-FMC); 3-fluro-N-methylcathinone;
[~~(71)~~] **(70)** (3-MMC); 3-methylmethcathinone;
[~~(72)~~] **(71)** (3,4 DMMC); 3,4-Dimethylmethcathinone;
[~~(73)~~] **(72)** (3-MEC); 3-Methyl-N-ethylcathinone;
[~~(74)~~] **(73)** 4-methylbuphedrone or 4-MeBP; 2-methylamino-1-(4-methylphenyl)butan-1-one
[~~(75)~~] **(74)** (4 MTA); 4-methylthioamphetamine;
[~~(76)~~] **(75)** (5-Me MDA); 5-methyl-3,4-methylenedioxyamphetamine;
[~~(77)~~] **(76)** (6-APB); 6-benzofuran;
[~~**(78)** (PMA); 4-methoxyamphetamine;~~
~~**(79)** (2C-B); 2,5-dimethoxy-4-bromophenethylamine;~~]
[~~(80)~~] **(77)** (2C-C); 2,5-dimethoxy-4-chlorophenethylamine;
[~~**(81)** (2C-D); 4-methyl-2,5-dimethoxyphenethylamine;~~
~~**(82)** (2C-E, aquarust, cindy); 2,5-dimethoxy-4-ethylphenethylamine;~~]
[~~(83)~~] **(78)** (2C-G); 3,4-dimethyl-2,5-dimethoxyphenethylamine;
[~~(84)~~] **(79)** (2C-I); 2,5-dimethoxy-4-iodophenethylamine;
[~~(85)~~] **(80)** (2C-T21); 2-[2,5-dimethoxy-4-(2-fluoroethylthio)phenyl]ethanamine;
[~~(86)~~] **(81)** (2C-B-FLY); 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine;
[~~(87)~~] **(82)** Bromo-DragonFLY or 3C-Bromo-Dragonfly or DOB-Dragonfly; 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine;
[~~(88)~~] **(83)** (DOB); 2,5-Dimethoxy-4-bromoamphetamine;
[~~(89)~~] **(84)** (DOC); 2,5-Dimethoxy-4-chloroamphetamine;
[~~**(90)** (DOM); 2,5-Dimethoxy-4-methylamphetamine;~~]
[~~(91)~~] **(85)** (TMA2); 2,4,5-trimethoxyamphetamine;
[~~(92)~~] **(86)** (TMA6); 2,4,6-trimethoxyamphetamine;
[~~(93)~~] **(87)** (MDAT); 6,7-methylenedioxy-2-aminotetralin;
[~~(94)~~] **(88)** (4-acetoxy DiPT, ipracetin); 4-acetoxy-N,N-diisopropyltryptamine;
[~~(95)~~] **(89)** (4-acetoxy DMT, psilacetin;) O-Acetylpsilocin;
[~~(96)~~] **(90)** 4-HO MET, metocin; 4-hydroxy-N-methyl-N-ethyltryptamine;
[~~(97)~~] **(91)** 4-HO MiPT, hats; 4-hydroxy-N-methyl-N-isopropyltryptamine;
[~~(98)~~] **(92)** 5-MeO-aMT, Alpha-O; 5-methoxy-α-methyltryptamine;
[~~(99)~~] **(93)** (5-MeO-MiPT); N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine;
[~~(100)~~] **(94)** (DiPT); N,N-diisopropyltryptamine;
[~~(101)~~] **(95)** (DPT); dipropyltryptamine;
[~~(102)~~] **(96)** (5-MeO-DALT); N,N-diallyl-5-methoxytryptamine;
[~~(103)~~] **(97)** (3-MeO PCP); 3-methoxyphencyclidine;
[~~(104)~~] **(98)** (4-MeO PCP); 4-methoxyphencyclidine;
[~~(105)~~] **(99)** (MK-801); dizocilpine;
[~~**(106)** (PCE, perchloroethylene, perchloroethene), Perc; tetrachloroethylene;~~
~~**(107)** (PCE, perchloroethylene, perchloroethene), Perc; tetrachloroethylene;~~]
[~~(108)~~] **(100)** (PCPr); phencyclamine, N-(1-phenylcyclohexyl)propanamine;
[~~(109)~~] **(101)** [~~(~~] Tenocyclidine or TCP [~~)~~]; 1-(1-(2-thienyl)cyclohexyl)piperidine

[~~(110)~~] **(102)** (3-MeO PCE); 3-methoxyeticyclidine, N-ethyl-1-(3-methoxyphenyl)cyclohexanamine;

[~~(111)~~] **(103)** (ETH-LAD); 6-ethyl-6-nor-lysergic acid diethylamide;

[~~(112~~] **(104)** (AL-LAD); 6-allyl-6-nor-LSD;

[~~(113)~~] **(105)** (PRO-LAD); 10-didehydroergoline-8-carboxamide;

[~~**(114)** ((1 (1,3 benzodioxol 5 yl) 2 (ethylamino)pentan 1 one, N ethylpentylone);~~]

[~~(115)~~] **(106)** (MPHP), 4′-methyl-alpha-pyrrolidinohexiophenone;

[~~(116)~~] **(107)** 4'-chloro-alpha-pyrrolidinovalerophenone (4-chloro-α-PVP; 4'-chloro-α-pyrrolidinopentiophenone);

[~~(117)~~] **(108)** 4-methyl-alpha-ethylaminopentiophenone (4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one);

[~~(118)~~] **(109)** Alpha-pyrrolidinoheptaphenone (PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one);

[~~(119)~~] **(110)** Alpha-pyrrolidinohexanophenone (α-PHP; α-pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one);

[~~(120)~~] **(111)** N-ethylhexedrone (α-ethylaminohexanophenone; 2-(ethylamino)-1-phenylhexan-1-one);

[~~(121)~~] **(112)** Methoxetamine; 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one; 2-(3-methoxyphenyl)-2-(N-ethylamino)cyclohexanone; MXE).

(113) 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine; TCPy;

(114) Alpha- Pyrrolidinoisohexanophenone or α-PHiP or A-PiHP; (4-methyl-1-phenyl-2-(pyrrolidin-1- YL) pentan-1 one);

(115) MDEA; 3,4-Methylenedioxy-N-ethylamphetamine;

(116) MePPP; 4-methyl-α-pyrrolidinopropiophenone; 1-(4- methylphenyl)-2-(pyrrolidin-1-yl)-propan-1-one;

(117) Dipentylone; 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)pentan-1-one;

F. Any material, compound, mixture or preparation which contains any quantity of the following substances.

(1) 3, 4-methylenedioxymethamphetamine (MDMA), its optical, positional and geometric isomers, salts and salts of isomers;

(2) (MPPP); 1-methyl-4-phenyl-4-proprionoxypiperidine its optical isomers, salts, and salts of isomers;

(3) 1-(-2-phenylethyl)-4-phenyl-4-acetoxy piperidine (PEPAP), its optical isomers, salts and salts of isomers;

(4) Cathinone;

(5) Methcathinone;

(6) Tianeptine;

(7) Para- Methoxymethamphetamine (PMMA)

[16.19.20.65 NMAC - Rp 16.19.20.65 NMAC, 6/26/2018; A, 12/17/2019; A, 9/14/2021; A, 6/13/2023; A, 11/17/2026]

16.19.20.66 SCHEDULE II:

A. Opioids: Unless specifically excepted or unless in another schedule any of the following opioids, including its isomers, esters, ethers, salts and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation except dextro and levopropoxyphene.

(1) Alphaprodine;

(2) Anileridine;

(3) Bezitramide;

(4) Diphenoxylate;

(5) Dihydrocodeine;

(6) Dextropropoxyphene (bulk) non-dosage form;

(7) Fentanyl;

(8) Isomethadone;

(9) Levomethorphan;

(10) Levorphanol;

(11) Metazocine;
(12) Methadone;
(13) Methadone intermediate; 4-cyano-2-dimethylamino-4, 4-diphenylbutane;
(14) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenyl-propane-carboxylic acid;
(15) Pethidine; or Meperidine or Demerol;
(16) Pethidine intermediate A; 4-cyano-1-methyl-4-phenylpiperidine;
(17) Pethidine intermediate B or Norpethidine; ethyl-4-phenyl-piperdine-4-carboxylate;
(18) Pethidine intermediate C or Pethidinic acid; 1-methyl-4-phenylpiperidine-4-carboxylic acid;
(19) Phenazocine;
(20) Piminodine;
(21) Racemethorphan;
(22) Racemorphan;
(23) Sufentanil;
(24) Carfentanil;
(25) (LAAM); Levo-alphacetylmethadol;
(26) Tapentadol;
(27) Thiafentanil;
(28) Norfentanyl;
(29) Oliceridine.
(30) ANPP; despropionyl fentanyl;
(31) Noroxymorphone;

B. Shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section. Substance, vegetable origin or chemical synthesis. Unless specifically exempt or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis.

(1) Opium and opiate, and any salts, compound, derivative, or preparation of opium or opiate excluding naloxone, dextrorphan, nalbuphine, naltrexone and apomorphine but including the following:
(a) Raw opium;
(b) Opium extracts;
(c) Opium fluid extracts;
(d) Powdered opium;
(e) Granulated opium;
(f) Tincture of opium;
(g) Codeine;
(h) Ethylmorphine;
(i) Etorphine hydrochloride;
(j) Hydrocodone;
(k) Hydromorphone;
(l) Metopon;
(m) Morphine;
(n) Oxycodone;
(o) Oxymorphone;
(p) Thebaine;
(q) Alfentanil;
(r) Oripavine.

(2) Any salt, compound derivative, or preparation thereof, which is chemically equivalent or identical with any of the substances referred to in Paragraph (1) of Subsection A of 16.19.20.66 NMAC, except that these substances shall not include the isoquinoline alkaloids of opium.

(3) Opium poppy and poppy straw.

(4) Coca leaves and any salt, compound, derivative or preparation of coca leaves and any salt, compound, derivative or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include de-cocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine.

C. Stimulants: Unless specifically exempt or unless listed in another schedule, any material,

compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system. (See 16.19.21 NMAC- Drug Precursors)

(1) Amphetamine, its salts, optical isomers and salts of its optical isomers.

(2) Methamphetamine, its salts, isomers and salts of isomers.

(3) Phenmetrazine and its salts.

(4) Methylphenidate.

(5) Lisdexamfetamine.

D. Depressants: Unless specifically exempt or unless listed in another schedule any material, compound mixture or preparation which contains any quantity of the substance having a depressant effect on the central nervous system, including its salts, isomers and salts of isomers is possible within the specific chemical designation.

(1) Amobarbital;

(2) Secobarbital;

(3) Pentobarbital;

(4) Phencyclidine;

(5) Glutethimide;

(6) 1-phenylcyclohexylamine;

(7) 1-piperidinocyclohexanecarbonitrile;

(8) Dronabinol in an oral solution in a drug product approved for marketing by the U.S. Food and Drug Administration.

E. Hallucinogenic substances: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (for purpose of this paragraph only, the term "isomers" includes the optical, positional, and geometric isomers):

(1) Nabilone;

(2) Phenylacetone (P2P, benzyl methyl ketone; methyl benzyl ketone).

F. Miscellaneous:

(1) Dihydroetorphine;

(2) Bulk dextropropoxyphene;

(3) Remifentanil.

[16.19.20.66 NMAC - Rp 16.19.20.66 NMAC, 6/26/2018; A, 12/17/2019; A, 6/13/2023; A, 11/17/2026]

16.19.20.67 SCHEDULE III: Shall consist of drugs and other substances, by whatever official name, common or usual name designated listed in this section.

A. Narcotic drugs: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation containing limited quantities of the following narcotic drugs, or any salts thereof.

(1) Not more than one and eight-tenths grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium.

(2) Not more than one and eight-tenths grams of codeine per 100 milliliters or not more than 90 milligrams per dosage units, with one or more active nonnarcotic ingredients in recognized therapeutic amounts.

(3) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium.

(4) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(5) Not more than one and eight-tenths grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(6) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(7) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(8) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

B. Stimulants: Unless specifically exempt or unless listed in another schedule, any material,

compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system.

(1) Those compounds, mixtures or preparations in dosage unit form containing any stimulant, amphetamine, phenmetrazine or methamphetamine previously exempt, for which the exemption was revoked by FDA Regulation Title 21, Part 308.13, and any other drug of the quantitative composition shown in that regulation for those drugs or which is the same except that it contains a lesser quantity of controlled substances.

(2) Benzphetamine;

(3) Phendimetrazine;

(4) Chlorphentermine;

(5) Clortermine.

C. Depressants: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system.

(1) Any compound, mixture or preparation containing:

(a) Amobarbital;

(b) Secobarbital;

(c) Pentobarbital;

(d) Butalbital; or any salt thereof and one or more active medicinal ingredients which are not listed in any schedule.

(2) Any suppository dosage form containing:

(a) Amobarbital;

(b) Secobarbital;

(c) Pentobarbital; or any salt of any of these drugs approved by the FDA for marketing only as a suppository.

(3) Any substance which contains any quantity of a derivative of barbituric acid or any salt of a derivative of barbituric acid.

(4) Chlorhexadol;

(5) Lysergic Acid;

(6) Lysergic Acid Amide;

(7) Methyprylon;

(8) Sulfondiethylmethane;

(9) Sulfonethylmethane;

(10) Sulfonmethane;

(11) Telazol; Tiletamine/zolazepam;

(12) Ketamine Hydrochloride.

(13) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under Section 505 of the Federal Food, Drug and Cosmetic Act.

(14) Embutramide;

(15) Dronabinol (synthetic) in sesame oil and encapsulated in soft gelatin capsules in a drug product approved by the U.S. food and drug administration.

(16) Perampanel.

D. Miscellaneous:

(1) Nalorphine (a narcotic drug);

(2) Buprenorphine;

(3) Clenbuterol.

E. Anabolic steroids: The term "anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, [~~and~~] corticosteroids, and dehydroepiandrosterone) [~~that promotes muscle growth~~] includes (but is not limited to) the substances listed below The drug or substance has been created or manufactured with the intent of producing a drug or other substance that either;

(1) Promotes muscle growth; or

(2) Otherwise causes a pharmacological effect similar to that of testosterone; or

(3) The drug or substance has been, or is intended to be, marketed or otherwise promoted in any manner suggesting that consuming it will promote muscle growth or any other pharmacological effect similar to that of testosterone. Unless specifically exempt or unless listed in another schedule, any material, compound,

mixture or preparation which contains any quantity including its salts, esters and ethers of the following substances listed in this section:

(1) Androstanedione; 5α-Androstan-3,17-dione;

(2) Kneller's Trione; 5α-Androstan-3,6,17-trione;

(3) 1-Androstenediol (3β,17β-dihydroxy-5α-androst-1-ene);

(4) 1-Androstenediol (3α,17β-dihydroxy-5α-androst-1-ene);

(5) 4-Androstenediol (3β,17β-dihydroxy-androst-4-ene);

(6) 5-Androstenediol (3β,17β-dihydroxy-androst-5-ene);

(7) 1-Androstenedione (5α-androst-1-en-3,17-dione);

(8) 4-Androstenedione (androst-4-en-3,17-dione);

(9) 5-Androstenedione (androst-5-en-3,17-dione);

(10) Bolasterone; (7α,17α-dimethyl-17β-hydroxyandrost-4-en-3-one);

[~~(1)~~] **(11)** Boldenone; (17β-hydroxyandrost-1,4-diene-3-one);

(12) Boldione; (androsta-1,4-diene-3,17-dione);

(13) 6-Bromo-androsta-1,4-diene-3,17-dione;

(14) 6-Bromo-androstan-3,17-dione;

[~~(2)~~] **(15)** [~~Chloro testosterone;~~] Calusterone; (7β,17α-dimethyl-17β-hydroxyandrost-4-en-3-one);

(16) 4-Chloro-17α-methyl-androsta-1,4-diene-3,17β-diol;

(17) Chloromethylandrostenediol; 4-Chloro-17α-methyl-androst-4-ene-3β,17β-diol;

(18) 4-chloro-17α-methyl-17β-hydroxy-androst-4-en-3-one;

(19) 4-chloro-17α-methyl-17β-hydroxy-androst-4-ene-3,11-dione;

[~~(3)~~] **(20)** Clostebol or 4-Chlorotestosterone; [PD140.1](4-chloro-17β-hydroxyandrost-4-en-3-one);

[~~(4)~~] **(21)** Dehydrochlormethyltestosterone or Oral Turinabol; (4-chloro-17β-hydroxy-17α-methyl-androst-1,4-dien-3-one);

(22) Desoxymethyltestosterone or Madol; (17α-methyl-5α-androst-2-en-17β-ol);

[~~(5)~~] **(23)** [~~Dihydrotestosterone~~] 4-dihydrotestosterone; (17β-hydroxy-androstan-3-one);

(24) Δ1-dihydrotestosterone or 1-testosterone; (17β-hydroxy-5α-androst-1-en-3-one);

(25) 3β,17β-dihydroxy-5α-androstane;

(26) 3α,17β-dihydroxy-5α-androstane;

(27) 2α,17α-dimethyl-17β-hydroxy-5β-androstan-3-one;

[~~(6)~~] **(28)** Drostanolone; (17β-hydroxy-2α-methyl-5α-androstan-3-one);

(29) Methylepitiostanol; 2α,3α-epithio-17α-methyl-5α-androstan-17β-ol;

(30) Trendione; estra-4,9,11-triene-3,17-dione;

(31) 13β-ethyl-17β-hydroxygon-4-en-3-one;

[~~(7)~~] **(32)** Ethylestrenol; (17α-ethyl-17β-hydroxyestr-4-ene);

[~~(8)~~] **(33)** Fluoxymesterone; (9-fluoro-17α-methyl-11β,17β-dihydroxyandrost-4-en-3-one;

[~~(9)~~] **(34)** Formebolone; (2-formyl-17α-methyl-11α,17β-dihydroxyandrost-1,4-dien-3-one);

(35) Furazabol; (17α-methyl-17β-hydroxyandrostano[2,3-c]furazan);

(36) [3,2-c]furazan-5α-androstan-17β-ol;

(37) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;

(38) 4-hydroxy-19-nortestosterone (4,17β-dihydroxy-estr-4-en-3-one);

(39) 4-hydroxy-androst-4-ene-3,17-dione;

(40) 17β-hydroxy-androstano[2,3-d]isoxazole;

(41) 17β-hydroxy-androstano[3,2-c]isoxazole;

(42) 3β-hydroxy-estra-4,9,11-trien-17-one;

(43) 4-hydroxytestosterone (4,17β-dihydroxy-androst-4-en-3-one);

[~~(10)~~] **(44)** Mestanolone; (17α-methyl-17β-hydroxy-5α-androstan-3-one);

[~~(11)~~] **(45)** Mesterolone; (17α-methyl-17β-hydroxy-5α-androstan-3-one);

[~~(12)~~] **(46)** Methandienone or Methandrostenolone; (17α-methyl-17β-hydroxyandrost-1,4-dien-3-one);

[~~**(13)** Methandranone;~~]

[~~(14)~~] **(47)** Methandriol (17α-methyl-3β,17β-dihydroxyandrost-5-ene);

[~~**(15)** Methandrostenolone;~~]

(48) Methasterone; (2α,17α-dimethyl-5α-androstan-17β-ol-3-one or 2α,17α-dimethyl-17β-hydroxy-5α-androstan-3-one);

[~~(16)~~] **(49)** Methenolone; (1-methyl-17β-hydroxy-5α-androst-1-en-3-one);

(50) 17α-methyl-androsta-1,4-diene-3,17β-diol;

(51) 17α-methyl-5α-androstan-17β-ol;

(52) 17α-methyl-androstan-3-hydroxyimine-17β-ol;

(53) 6α-methyl-androst-4-ene-3,17-dione;

(54) 17α-methyl-androst-2-ene-3,17β-diol;

(55) 17α-methyl-3β,17β-dihydroxy-5α-androstane;

(56) 17α-methyl-3α,17β-dihydroxy-5α-androstane;

(57) 17α-methyl-3β,17β-dihydroxyandrost-4-ene;

(58) 17α-methyl-4-hydroxynandrolone (17α-methyl-4-hydroxy-17β-hydroxyestr-4-en-3-one);

(59) Methyldienolone; (17α-methyl-17β-hydroxyestra-4,9(10)-dien-3-one);

(60) 17α-methyl-Δ1-dihydrotestosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one) (a.k.a. "17-α-methyl-1-testosterone");

[~~(17)~~] **(61)** Methyltrienolone; (17α-methyl-17β-hydroxyestra-4,9,11-trien-3-one);

[~~(18)~~] **(62)** Methyltestosterone; (17α-methyl-17β-hydroxyandrost-4-en-3-one);

[~~(19)~~] **(63)** Mibolerone; (7α,17α-dimethyl-17β-hydroxyestr-4-en-3-one);

[~~(20)~~] **(64)** Nandrolone; (17β-hydroxyestr-4-en-3-one);

(65) 19-nor-4-androstenediol (3β,17β-dihydroxyestr-4-ene);

(66) 19-nor-4-androstenediol (3α,17β-dihydroxyestr-4-ene);

(67) 19-nor-5-androstenediol (3β,17β-dihydroxyestr-5-ene);

(68) 19-nor-5-androstenediol (3α,17β-dihydroxyestr-5-ene);

(69) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);

(70) 19-nor-4-androstenedione (estr-4-en-3,17-dione);

(71) 19-nor-5-androstenedione (estr-5-en-3,17-dione);

[~~(21)~~] **(72)** Norbolethone; (13β,17α-diethyl-17β-hydroxygon-4-en-3-one);

(73) Norclostebol; (4-chloro-17β-hydroxyestr-4-en-3-one);

[~~(22)~~] **(74)** Norethandrolone; (17α-ethyl-17β-hydroxyestr-4-en-3-one);

(75) Normethandrolone; (17α-methyl-17β-hydroxyestr-4-en-3-one);

[~~(23)~~] **(76)** Oxandrolone; (17α-methyl-17β-hydroxy-2-oxa-5α-androstan-3-one);

[~~(24)~~] **(77)** Oxymesterone; (17α-methyl-4,17β-dihydroxyandrost-4-en-3-one);

[~~(25)~~] **(78)** Oxymetholone; (17α-methyl-2-hydroxymethylene-17β-hydroxy-5α-androstan-3-one);

(79) Prostanozol; (17β-hydroxy-5α-androstano[3,2-c]pyrazole or [3,2-c]pyrazole-5α-androstan-17β-ol);

(80) [3,2-c]pyrazole-androst-4-en-17β-ol;

[~~(26)~~] **(81)** Stanolone or Dihydrotestosterone; 5α-androstan-17β-ol-3-one;

[~~(27)~~] **(82)** Stanozolol; (17α-methyl-17β-hydroxy-5α-androst-2-eno[3,2-c]-pyrazole);

(83) Stenbolone (17β-hydroxy-2-methyl-5α-androst-1-en-3-one);

[~~(28)~~] **(84)** Testolactone(13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid lactone);

[~~(29)~~] **(85)** Testosterone; (17β-hydroxyandrost-4-en-3-one);Tetrahydrogestrinone; (13β,17α-diethyl-17β-hydroxygon-4,9,11-trien-3-one);

[~~(30)~~] **(86)** Trenbolone(17β-hydroxyestr-4,9,11-trien-3-one);[~~and~~]

[~~(31)~~] **(87)** and any salt, ester, or isomer of a drug or substance described or listed in this paragraph, if that salt, ester, or isomer promotes muscle growth.

F. Exempt anabolic steroids: Compounds, mixtures, or preparations that contain an anabolic steroid that have been exempted by the board from Subsection E of 16.19.20.67 NMAC, schedule III to the same extent that the substance has been exempted from the application of the Federal Controlled Substance Act, if the substance is listed as an exempt anabolic steroid product under 21 C.F.R. Section 1308.34 and its subsequent amendments.

[16.19.20.67 NMAC - Rp 16.19.20.67 NMAC, 6/26/2018; A, 11/17/2026]

16.19.20.68 SCHEDULE IV: Shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.

A. Depressants: Unless specifically exempt or unless listed in another schedule, any material,

compound, mixture or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

(1) Alfaxalone;
(2) Alprazolam;
(3) Barbital;
(4) Chloral Betaine;
(5) Chloral Hydrate;
(6) Chlordiazepoxide;
(7) Clobazam;
(8) Clonazepam;
(9) Clorazepate;
(10) Clotiazepam
(11) Diazepam;
(12) Estazolam;
(13) Ethchlorvynol;
(14) Ethinamate;
(15) Flurazepam;
(16) Fospropofol;
(17) Halazepam;
(18) Lorazepam;
(19) Mebutamate;
(20) Meprobamate;
(21) Methohexital;
(22) Methylphenobarbital;
(23) Midazolam;
(24) Oxazepam;
(25) Paraldehyde;
(26) Petrichloral;
(27) Phenobarbital;
(28) Prazepam;
(29) Quazepam;
(30) Remimazolam;
(31) Suvorexant;
(32) Temazepam;
(33) Triazolam;
(34) Brexanolone.

B. Lorcaserin: Any material, compound, mixture or preparation which contains any quantity of the following substance, including its salts, isomers (whether optical, positional, or geometric) and its salts, or such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible: Lorcaserin.

C. Stimulants: Unless specifically exempt or unless listed in another schedule any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, positional, or geometric) and salts of such isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation:

(1) Diethylpropion;
(2) Phentermine;
(3) Pemoline (including organometallic complexes and chelates thereon);
(4) Pipradrol;
(5) SPA ((-)-1-dimethyl amino-1,2-diphenylmethane);
(6) Mazindol;
(7) Cathine;
(8) Fencamfamin;
(9) Fenproporex;
(10) Mefenorex;
(11) Modafinil;

(12) Sibutramine;
(13) Solriamfetol;
(14) Serdexmethylphenidate.

D. Other substances: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts:

(1) Dextropropoxyphene(Alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane);
(2) Pentazocine;
(3) Carisoprodol;
(4) Nalbuphine Hydrochloride;
(5) Butorphanol Tartrate;
(6) Dezocine;
(7) Dichloralphenazone;
(8) Zaleplon;
(9) Zolpidem;
(10) Eszopiclone;
(11) Tramadol;
(12) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical isomers) and its salts, isomers, and salts of isomers
(13) Lemborexant;
(14) Daridorexant
(15) Zuranolone;

E. Narcotic drug: Unless specifically exempt or unless listed in another schedule, any material, compound, mixture or preparation containing limited quantities of any of the following narcotic drugs or any salts thereof: Not more than one milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.

F. Exemption of chloral: When packaged in a sealed, oxygen-free environment, under nitrogen pressure, safeguarded against exposure to the air. Chloral when existing under the above conditions is a substance which is not intended for general administration to a human being or another animal, and contains no narcotic controlled substances and is packaged in such a form that the package quantity does not present any significant potential for abuse. All persons who engage in industrial activities with respect to such chloral are subject to registration; but shall be exempt from Section 30-31-16 through 19 of the New Mexico Controlled Substances Act and 16.19.20.19 NMAC through 16.19.20.52 NMAC of the board of pharmacy regulations.

G. Exempt compounds: Librax and Menrium are preparations which contain chlordiazepoxide, a depressant listed in schedule IV, Paragraph (6) of Subsection A of 16.19.20.68 NMAC and other ingredients in such combinations, quantity, preparation or concentration as to vitiate the potential for abuse of chlordiazepoxide, and are hereby exempt preparations.

(1) Librax;
(2) Menrium, 5-2;
(3) Menrium, 4-5;
(4) Menrium, 10-4.

[16.19.20.68 NMAC - Rp 16.19.20.68 NMAC, 6/26/2018; A, 9/14/2021; A, 6/13/2023; A, 11/17/2026]